11 Einträge gefunden

1. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

   1. Gaidzik, Verena I
   2. Paschka, Peter
   3. Schlenk, Richard F
   4. Weber, Daniela
   5. Fröhling, Stefan
   6. Krämer, Alwin
   7. Wäsch, Ralph

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

   1. Kröger, Nicolaus
   2. Sockel, Katja
   3. Wolschke, Christine
   4. Bethge, Wolfgang
   5. Schlenk, Richard F
   6. Wolf, Dominik
   7. Stadler, Michael

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

   1. Hecht, Anna
   2. Meyer, Julia A
   3. Jann, Johann-Christoph
   4. Sockel, Katja
   5. Giagounidis, Aristoteles
   6. Götze, Katharina S
   7. Letsch, Anne

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin

   1. Teich, Katrin
   2. Krzykalla, Julia
   3. Kapp-Schwoerer, Silke
   4. Gaidzik, Verena I
   5. Schlenk, Richard F
   6. Paschka, Peter
   7. Weber, Daniela

   2021 - Forschungsinformationssystem des UKE
5. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

   1. Schlenk, Richard F
   2. Paschka, Peter
   3. Krzykalla, Julia
   4. Weber, Daniela
   5. Kapp-Schwoerer, Silke
   6. Gaidzik, Verena I
   7. Leis, Claudia

   2020 - Forschungsinformationssystem des UKE
6. Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

   1. Schlenk, Richard F
   2. Weber, Daniela
   3. Fiedler, Walter
   4. Salih, Helmut R
   5. Wulf, Gerald
   6. Salwender, Hans
   7. Schroeder, Thomas

   2019 - Forschungsinformationssystem des UKE
7. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

   1. Döhner, Hartmut
   2. Müller-Tidow, Carsten
   3. Lübbert, Michael
   4. Fiedler, Walter
   5. Krämer, Alwin
   6. Westermann, Jörg
   7. Bug, Gesine

   2019 - Forschungsinformationssystem des UKE
8. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

   1. Krauter, Jürgen
   2. Fiedler, Walter
   3. Schlenk, Richard F
   4. Paschka, Peter
   5. Thol, Felicitas
   6. Lübbert, Michael
   7. Wattad, Mohammed

   2018 - Forschungsinformationssystem des UKE
9. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial

   1. Paschka, Peter
   2. Schlenk, Richard F
   3. Weber, Daniela
   4. Benner, Axel
   5. Bullinger, Lars
   6. Heuser, Michael
   7. Gaidzik, Verena I

   2018 - Forschungsinformationssystem des UKE
10. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

    1. Braulke, Friederike
    2. Schulz, Xenia
    3. Germing, Ulrich
    4. Schuler, Esther
    5. Platzbecker, Uwe
    6. Nolte, Florian
    7. Hofmann, Wolf-Karsten

    2017 - Forschungsinformationssystem des UKE
11. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

    1. Schlenk, Richard F
    2. Lübbert, Michael
    3. Benner, Axel
    4. Lamparter, Alexander
    5. Krauter, Jürgen
    6. Herr, Wolfgang
    7. Martin, Hans

    2016 - Forschungsinformationssystem des UKE